Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $17.6667.

Several equities research analysts have commented on AMRX shares. UBS Group boosted their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. Finally, Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th.

Amneal Pharmaceuticals Stock Down 2.1%

AMRX stock opened at $18.07 on Friday. Amneal Pharmaceuticals has a 52 week low of $8.01 and a 52 week high of $19.26. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The firm has a 50-day simple moving average of $16.69 and a 200-day simple moving average of $14.42. The stock has a market capitalization of $5.76 billion, a P/E ratio of 36.88 and a beta of 1.27.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The firm had revenue of $722.52 million for the quarter. Equities analysts forecast that Amneal Pharmaceuticals will post 0.92 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 17.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AMRX. Bank of New York Mellon Corp acquired a new position in Amneal Pharmaceuticals during the second quarter worth about $17,573,000. Handelsbanken Fonder AB lifted its stake in Amneal Pharmaceuticals by 3.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company’s stock worth $1,322,000 after purchasing an additional 2,200 shares in the last quarter. Bank of America Corp DE lifted its stake in Amneal Pharmaceuticals by 50.0% in the 1st quarter. Bank of America Corp DE now owns 676,795 shares of the company’s stock worth $8,413,000 after purchasing an additional 225,637 shares in the last quarter. Arkadios Wealth Advisors acquired a new position in shares of Amneal Pharmaceuticals during the 1st quarter worth approximately $4,165,000. Finally, California State Teachers Retirement System boosted its holdings in shares of Amneal Pharmaceuticals by 37.6% during the 1st quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock worth $2,576,000 after purchasing an additional 56,588 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.